We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Seizures Post Intracerebral Hemorrhage

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01115959
First Posted: May 4, 2010
Last Update Posted: June 12, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Dr. Yair Lampl, Wolfson Medical Center
  Purpose
This study examines early antiepileptic treatment with valproic acid for acute cerebral hemorrhage against a placebo group immediately post event to evaluate the outcome of these patients regarding seizures and neurological outcome.

Condition Intervention Phase
Post Cerebral Hemorrhage Drug: valproic acid Drug: placebo bid Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Are Post Intracerebal Hemorrhage Prevented By Anti-Epileptic Treatment?

Resource links provided by NLM:


Further study details as provided by Dr. Yair Lampl, Wolfson Medical Center:

Primary Outcome Measures:
  • number of seizures [ Time Frame: study drug for 1 month and 1 year follow up ]

Secondary Outcome Measures:
  • neurological outcome NIHSS [ Time Frame: during 1 month study drug and 1 year post follow up ]

Enrollment: 72
Study Start Date: February 2003
Study Completion Date: December 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: valproic acid
Valproic acid given orally 400mg twice daily
Drug: valproic acid
treatment of 1 month dosage of 400 mg BID
Drug: placebo bid
Placebo Comparator: placebo
Placebo twice daily for one month
Drug: placebo bid

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • cerebral hemorrhage spontaneous

Exclusion Criteria:

  • early seizures
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01115959


Sponsors and Collaborators
Wolfson Medical Center
Investigators
Principal Investigator: ronit gilad, md E Wolfson med center
Principal Investigator: ronit gilad, md E wofson med center
  More Information

Responsible Party: Dr. Yair Lampl, Professor Yair Lampl, Wolfson Medical Center
ClinicalTrials.gov Identifier: NCT01115959     History of Changes
Other Study ID Numbers: 001
First Submitted: May 2, 2010
First Posted: May 4, 2010
Last Update Posted: June 12, 2014
Last Verified: May 2010

Additional relevant MeSH terms:
Hemorrhage
Cerebral Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Valproic Acid
Anticonvulsants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs